Provided by Tiger Trade Technology Pte. Ltd.

Fortress Biotech

3.27
+0.340011.60%
Post-market: 3.26-0.0100-0.31%19:47 EST
Volume:627.39K
Turnover:1.99M
Market Cap:101.49M
PE:-11.16
High:3.27
Open:3.02
Low:3.00
Close:2.93
52wk High:4.53
52wk Low:1.33
Shares:31.04M
Float Shares:23.51M
Volume Ratio:1.04
T/O Rate:2.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2930
EPS(LYR):-2.6890
ROE:-205.29%
ROA:-34.25%
PB:1.82
PE(LYR):-1.22

Loading ...

Fortress Biotech Gains FDA Approval for Menkes Treatment

TIPRANKS
·
Jan 13

Fortress Biotech Shares Hit Near Two-Week Low, Last Down 6.6%

THOMSON REUTERS
·
Jan 13

FDA Approves Fortress Biotech’s ZYCUBO for Menkes Disease

Reuters
·
Jan 13

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of Zycubo® (Copper Histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

THOMSON REUTERS
·
Jan 13

Fortress Biotech Inc - Cyprium Eligible for up to $129 Mln in Milestones

THOMSON REUTERS
·
Jan 13

Fortress Biotech Inc - Rare Pediatric Disease Voucher to Be Transferred to Cyprium

THOMSON REUTERS
·
Jan 13

Fortress Biotech Climbs on Revised Credit Agreement

Dow Jones
·
Jan 13

Avenue Therapeutics Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 31, 2025

Mustang Bio Director David Jin Reports Acquisition of Common Shares

Reuters
·
Dec 31, 2025

Mustang Bio Inc. held annual shareholder meeting

Reuters
·
Dec 24, 2025

Fortress Biotech Announces Unregistered Sale of Warrants in Private Placement

Reuters
·
Dec 16, 2025

FDA Accepts Fortress Biotech and Cyprium Therapeutics CUTX-101 NDA Resubmission

Reuters
·
Dec 15, 2025

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of Cutx-101 Nda Resubmission

THOMSON REUTERS
·
Dec 15, 2025

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (Dfd-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

THOMSON REUTERS
·
Dec 10, 2025

Avenue Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 06, 2025

Mustang Bio Inc. Announces Date for Upcoming Annual Stockholder Meeting

Reuters
·
Dec 04, 2025

Fortress Biotech Jumps in Volume Spike, Last up 3.7%

THOMSON REUTERS
·
Dec 04, 2025

BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA

Reuters
·
Nov 17, 2025

Sentynl Resubmits CUTX-101 NDA to FDA for Menkes Disease Treatment

Reuters
·
Nov 17, 2025

Fortress Biotech Inc: on Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted the Nda for Cutx-101 to the FDA

THOMSON REUTERS
·
Nov 17, 2025